Imaging in Central Nervous System Drug Discovery

详细信息    查看全文

• 作者：Roger N. Gunn ; PhD^* ; ^&dagger ; ; ^&Dagger ; ; ^{roger.gunn@imanova.co.uk} ; Eugenii A. Rabiner ; FCPsych (SA)^* ; ^§ ;
• 刊名：Seminars in Nuclear Medicine
• 出版年：2017
• 出版时间：January 2017
• 年：2017
• 卷：47
• 期：1
• 页码：89-98
• 全文大小：1497 K
• 卷排序：47

文摘

The discovery and development of central nervous system (CNS) drugs is an extremely challenging process requiring large resources, timelines, and associated costs. The high risk of failure leads to high levels of risk. Over the past couple of decades PET imaging has become a central component of the CNS drug-development process, enabling decision-making in phase I studies, where early discharge of risk provides increased confidence to progress a candidate to more costly later phase testing at the right dose level or alternatively to kill a compound through failure to meet key criteria. The so called “3 pillars” of drug survival, namely; tissue exposure, target engagement, and pharmacologic activity, are particularly well suited for evaluation by PET imaging. This review introduces the process of CNS drug development before considering how PET imaging of the “3 pillars” has advanced to provide valuable tools for decision-making on the critical path of CNS drug development. Finally, we review the advances in PET science of biomarker development and analysis that enable sophisticated drug-development studies in man.